(Q43264777)

English

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study

scientific article published on 9 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 November 2017

A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study (English)

1 reference

Europe PubMed Central

17 November 2017

1 reference

based on heuristic

inferred from title

essential hypertension

1 reference

based on heuristic

inferred from title

author name string

Toshio Ogihara

1

1 reference

Europe PubMed Central

17 November 2017

Takao Saruta

2

1 reference

Europe PubMed Central

17 November 2017

Kazuyuki Shimada

3

1 reference

Europe PubMed Central

17 November 2017

Kizuku Kuramoto

4

1 reference

Europe PubMed Central

17 November 2017

publication date

9 October 2009

1 reference

Europe PubMed Central

17 November 2017

Hypertension Research

1 reference

Europe PubMed Central

17 November 2017

32

1 reference

Europe PubMed Central

17 November 2017

12

1 reference

Europe PubMed Central

17 November 2017

1148-1154

1 reference

Europe PubMed Central

17 November 2017

https://scigraph.springernature.com/pub.10.1038/hr.2009.163

0 references

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.163

21 January 2018

Identifiers

10.1038/HR.2009.163

1 reference

Europe PubMed Central

17 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

17 November 2017

reason for deprecated rank

incorrect identifier value

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43264777&oldid=1985100229"